Hypertension
Conditions
Keywords
high blood pressure, antihypertensive drugs, sexual dysfunction
Brief summary
Several studies describe the existence of an association between sexual dysfunction and high blood pressure (hypertension), most often characterized by a decrease in the number of orgasms and the existence of dyspareunia. Hypertension is a contributing factor, and nonadherence to medication could amplify it. There are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and / or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments. The investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers. The main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.
Interventions
BIOLOGICALBlood sample for the determination of antihypertensives or their metabolites.
15 ml of Blood sample for the determination of antihypertensives or their metabolites
BEHAVIORALQuestionnaire on sexual activity
Questionnaire on sexual activity in women
BEHAVIORALScale on hospital anxiety and depression
Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
BEHAVIORALMorisky Questionaire
anti-hypertensive medication compliance questionnaire
Sponsors
University Hospital, Toulouse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women over 18, * Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine, * Having signed the informed consent form. * Beneficiary or affiliated to a French Social insurance
Exclusion criteria
* Patients with bariatric surgery, * Patients under guardianship/trusteeship/protection of justice, * Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analyse of sexual dysfunction | 25 months | Prevalence of sexual dysfunction defined by a score less than 26 on the Female Sexual Function Index scale : score less than 26 mean a sexual dysfunction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with a good medication compliance by drug dosages and the Morisky questionnaire | 25 months | Compare two methods of assessing drug compliance: drug dosages in the blood and the Morisky questionnaire; The score is rated on 8 points. A score of 8 is considered "good observant", a score between 6 and 7 "moderately observant patient" and a score strictly lower than 6 "poor observant". |
| Number of cases with sexual dysfunction in hypertensive women according to the antihypertensive pharmacological classes used | 25 months | Estimate the prevalence of sexual dysfunction according to the antihypertensive pharmacological classes used (in the biologicale analysis) |
| Number of cases with sexual dysfunction in hypertensive women according to the number of antihypertensive treatments; | 25 months | Estimate the prevalence of sexual dysfunction according to the number of antihypertensive treatments; |
Countries
France
Contacts
CONTACTDelphine LAZARO-VERGE
PRINCIPAL_INVESTIGATORDelphine LAZARO-VERGE, MD
University Hospital, Toulouse
Outcome results
None listed